Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment
- PMID: 27515050
- DOI: 10.1007/s12272-016-0795-8
Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment
Abstract
Signal transducer and activator of transcription 3 (STAT3) is a cytoplasmic transcription factor that modulates the transcription of a variety of genes to regulate important biological functions, including cell proliferation, differentiation, survival, angiogenesis, and immune response. Constitutive activation of STAT3 is important in oncogenic signaling and occurs at high frequency in human cancers, including diverse solid tumors and hematologic malignancies. Moreover, it is associated with a poor prognosis. The tumor microenvironment has recently been recognized as a key condition for cancer progression, invasion, angiogenesis, metastasis, and drug resistance by activation of STAT3 signaling. Therefore, understanding the biology associated with STAT3-mediated signaling cascades in the tumor microenvironment may offer the therapeutic potential to treat human cancers. This review presents an overview of the critical roles of STAT3 in the tumor microenvironment related to cancer biology and discusses recent advancements in the development of anticancer drugs that therapeutically inhibit STAT3 signaling cascades.
Keywords: Cancer; Inflammation; Signal transducer and activator of transcription 3 (STAT3); Tumor microenvironment.
Similar articles
-
Highlighted STAT3 as a potential drug target for cancer therapy.BMB Rep. 2019 Jul;52(7):415-423. doi: 10.5483/BMBRep.2019.52.7.152. BMB Rep. 2019. PMID: 31186087 Free PMC article. Review.
-
Signal transducer and activator of transcription 3 inhibitors: a patent review.Expert Opin Ther Pat. 2011 Jan;21(1):65-83. doi: 10.1517/13543776.2011.539205. Epub 2010 Nov 29. Expert Opin Ther Pat. 2011. PMID: 21114420 Review.
-
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer.Expert Opin Investig Drugs. 2015 Jun;24(6):809-24. doi: 10.1517/13543784.2015.1020370. Epub 2015 Mar 7. Expert Opin Investig Drugs. 2015. PMID: 25746129 Review.
-
The JAK/STAT3 axis: A comprehensive drug target for solid malignancies.Semin Cancer Biol. 2017 Aug;45:13-22. doi: 10.1016/j.semcancer.2017.06.001. Epub 2017 Jun 21. Semin Cancer Biol. 2017. PMID: 28647610 Review.
-
Signal transducer and activator of transcription 3 (STAT3): a promising target for anticancer therapy.Future Med Chem. 2011 Apr;3(5):567-97. doi: 10.4155/fmc.11.22. Future Med Chem. 2011. PMID: 21526897 Review.
Cited by
-
Mitochondrial Dynamics, ROS, and Cell Signaling: A Blended Overview.Life (Basel). 2021 Apr 10;11(4):332. doi: 10.3390/life11040332. Life (Basel). 2021. PMID: 33920160 Free PMC article. Review.
-
Oxidative stress regulation and related metabolic pathways in epithelial-mesenchymal transition of breast cancer stem cells.Stem Cell Res Ther. 2023 Nov 28;14(1):342. doi: 10.1186/s13287-023-03571-6. Stem Cell Res Ther. 2023. PMID: 38017510 Free PMC article. Review.
-
Highlighted STAT3 as a potential drug target for cancer therapy.BMB Rep. 2019 Jul;52(7):415-423. doi: 10.5483/BMBRep.2019.52.7.152. BMB Rep. 2019. PMID: 31186087 Free PMC article. Review.
-
Interleukin-22 modulates cisplatin sensitivity of osteosarcoma cells by regulating the STAT3 signaling pathway.Exp Ther Med. 2020 Feb;19(2):1379-1387. doi: 10.3892/etm.2019.8352. Epub 2019 Dec 19. Exp Ther Med. 2020. PMID: 32010312 Free PMC article.
-
Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment.Front Cell Dev Biol. 2021 Mar 1;9:641469. doi: 10.3389/fcell.2021.641469. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33732706 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
